Try our beta test site
30 studies found for:    "Myelodysplastic Syndromes" | Switzerland
Show Display Options
Rank Status Study
1 Completed Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Interventions: Drug: ATG + CSA;   Behavioral: Supportive care
2 Recruiting ARGX-110 With AZA in AML or High Risk MDS
Conditions: Acute Myeloid Leukemia;   High Risk Myelodysplastic Syndrome
Intervention: Drug: ARGX-110 with AZA
3 Completed Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Other: medical chart review;   Other: questionnaire administration;   Procedure: quality-of-life assessment
4 Unknown  Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Drug: cytarabine;   Drug: etoposide;   Drug: idarubicin;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
5 Withdrawn Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Intervention: Biological: lintuzumab
6 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo
7 Completed Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: CC-5013
8 Completed Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: thioguanine
9 Active, not recruiting Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Drug: Deferasirox placebo
10 Active, not recruiting A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Conditions: Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine;   Drug: 5-Azacytidine
11 Active, not recruiting
Has Results
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: MDS
Interventions: Drug: Darbepoetin alfa;   Drug: Placebo
12 Completed A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag;   Drug: Azacitidine;   Drug: Placebo
13 Recruiting Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention: Drug: Azacitidine
14 Unknown  Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome
Conditions: Anemia;   Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa;   Drug: amifostine trihydrate
15 Unknown  Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Drug: decitabine
16 Completed Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: gemtuzumab ozogamicin;   Drug: idarubicin;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
17 Completed NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
Conditions: Leukemia, Myeloid, Acute;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Myelodysplastic Syndromes;   Lymphoma;   Neuroblastoma;   Rhabdomyosarcoma
Intervention: Biological: CD3-depleted/CD56+ selected natural killer cells collected from apheresis products
18 Unknown  Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation
19 Recruiting Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation
Condition: Invasive Aspergillosis
Intervention:
20 Active, not recruiting A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005)
Conditions: AML Including AML de Novo and AML Secondary to MDS;   DLBCL
Interventions: Drug: MK-8628 Dose A;   Drug: MK-8628 Dose B

   Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.